Result of AGM

Belluscura PLC

14 September 2023

 

 14 September 2023 

Belluscura plc

("BELL" or the "Company")

Result of AGM

Belluscura plc (AIM: BELL) announces that at the Annual General Meeting ("AGM") held earlier today all the resolutions put to the meeting were duly approved by shareholders: 

Resolution (*indicates special resolution)	Votes for	% of shares voted	Votes against	% of shares voted	Votes withheld
Resolution 1: To receive and adopt the report of the directors and the audited accounts of the Company for the period ended 31 December 2022	52,474,602	99.67%	175,911	0.33%	0
Resolution 2: To re-elect Mr David Poutney as a director of the Company.	52,471,268	99.67%	175,911	0.33%	3,334
Resolution 3. To re-elect Dr Patrick Strollo as a director of the Company.	52,628,453	99.96%	22,060	0.04%	0
Resolution 4: To re-appoint Gerald Edelman LLP as auditors.	52,628,453	99.96%	22,060	0.04%	0
Resolution 5: To authorise the directors to determine the remuneration of the auditors.	52,628,453	99.96%	22,060	0.04%	0
Resolution 6: To grant the directors authority to allot shares pursuant to Section 551 of the Companies Act 2006 and grant rights to subscribe for, or convert any security into, shares.	52,601,892	99.91%	48,621	0.09%	0
Resolution 7*: To dis-apply pre-emption rights pursuant to Section 570 of the Companies Act 2006.	52,601,892	99.91%	48,621	0.09%	0
Resolution 8*: To authorise the directors to make market purchases.	52,640,513	99.98%	10,000	0.02%	0

*Special resolutions

For further information please contact:

Belluscura plc	Tel: [phone]
Adam Reynolds, Chairman Robert Rauker, Chief Executive Officer Anthony Dyer, Chief Financial Officer
SPARK Advisory Partners Limited Nominated Adviser	Tel: [phone]
Neil Baldwin / Jade Bayat
Dowgate Capital Limited Broker	Tel: [phone]
James Serjeant / Russell Cook
MHP Financial PR & Investor Relations	Tel: [phone] email: [e-mail]
Katie Hunt / Matthew Taylor

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

END